Pharmaceutical

Oncternal stock crashes by 60% as it lays off staff and scraps trials

Oncternal is halting the development of two cancer candidates, ONCT-534 and ONCT-808, after disappointing trial results.

Sep 14, 2024 - 04:00
Oncternal stock crashes by 60% as it lays off staff and scraps trials
Oncternal is halting the development of two cancer candidates, ONCT-534 and ONCT-808, after disappointing trial results.
Read the original article

Tags:

Previous Article

Japan approves updated Covid-19 vaccine to tackle JN.1 variant

Next Article

Cidara axes 30% of staff to focus on flu prevention drug

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Sanofi becomes the third leading insulin maker to lower list prices, cutting Lantus price by 78%

STAT+: Sanofi becomes the third leading insulin maker t...

Mar 19, 2023

The evolving presence of AI in telemedicine for behavioural health

The evolving presence of AI in telemedicine for behavio...

Jan 17, 2024

STAT+: U.K. researchers warn about biases in medical devices, health care algorithms

STAT+: U.K. researchers warn about biases in medical de...

Mar 12, 2024